Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Clinical Trial Calendar
Results Date
Company Name
Ticker
Event
Indication
Outcome
Early 2026
Contineum Therapeutics Inc.,
CTNM
Topline data readout from Phase 1b trial of PIPE-791
Chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP)
Early 2026
Immatics N.V
IMTX
Pre-specified interim analysis data from Phase 3 trial of ACTengine IMA203
Second-line or later (2L+) unresectable or metastatic melanoma
Early 2026
Iovance Biotherapeutics, Inc.
IOVA
Initial results from Phase 2 trial of Lifileucel (IOV-END-201)
Advanced endometrial cancer
Early 2026
MoonLake Immunotherapeutics
MLTX
Topline data from Phase 2 trial of sonelokimab (S-OLARIS)
Axial spondyloarthritis (axSpA)
Positive results reported on Feb 22, 2026
Early 2026
AC Immune SA
ACIU
Interim results from Phase 2 trial of ACI-24.060 (ABATE)
Alzheimer's disease
Early 2026
BridgeBio Pharma, Inc.
BBIO
Topline results from Phase 3 trial of infigratinib (PROPEL 3)
Achondroplasia
Positive topline results reported on Feb 12, 2026
Early 2026
Aclaris Therapeutics
ACRS
Top line results from Phase 1a single ascending dose and multiple ascending dose portion of Phase 1a/1b trial of ATI-052
Immune-inflammatory diseases
Q2 2026
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI,
RICFY
Top-line results from Phase 2 trial of pasireotide
Post-bariatric hypoglycemia
Q2 2026
Avadel Pharmaceuticals plc
AVDL
Data from Phase 3 trial of LUMRYZ (REVITALYZ)
Idiopathic hypersomnia (IH)
Q2 2026
Wave Life Sciences Ltd.
WVE
Six-month follow-up data from 400 mg Cohort 3 of Phase 1 trial of WVE-007 (INLIGHT)
Obesity
Q2 2026
Wave Life Sciences Ltd.
WVE
Three-month follow-up data from 600 mg Cohort 4 Phase 1 trial of WVE-007 (INLIGHT)
Obesity
Q2 2026
Cullinan Therapeutics, Inc.
CGEM
Initial data from Phase 1 study of CLN-978 (OUTRACE)
Rheumatoid arthritis (RA)
Q2 2026
Kodiak Sciences Inc.
KOD
Topline data from Phase 3 trial of Tarcocimab (DAYBREAK)
Wet Age-Related Macular Degeneration
Q2 2026
Kodiak Sciences Inc.
KOD
Topline data from Phase 3 trial of KSI-501(DAYBREAK)
Wet Age-Related Macular Degeneration
Q2 2026
Curasight A/S
CUS.F
Topline data from Phase 1 trial of uTREAT
High-grade gliomas
Early Q2 2026
Lipocine Inc
LPCN
Topline safety and efficacy results from Phase 3 trial of LPCN 1154 (oral brexanolone)
Postpartum depression
study fails; reported on Apr 2, 2026
Q2 2026
Atrium Therapeutics, Inc.
RNA
Topline data from Phase 3 trial of delpacibart etedesiran (HARBOR)
Myotonic dystrophy type 1 (DM1)
Q2 2026
Ascendis Pharma A/S
ASND
78-week data from Phase II Trial of TransCon CNP in combination with TransCon hGH (COACH)
Achondroplasia in children
Q2 2026
NextCure Inc
NXTC
Data from Phase 1 open-label dose escalation study of SIM0505 (CDH6 ADC)
Advanced solid tumors including gynecological cancers and platinum resistant ovarian cancer
Q2 2026
Aquestive Therapeutics Inc.
AQST
Data readout from second Phase 1 trial of AQST-108
Alopecia areata (AA)
Q2 2026
Candel Therapeutics, Inc.
CADL
Follow-up clinical data from phase 3 trial of Aglatimagene besadenovec (CAN-2409)
Prostate cancer
Q2 2026
Rapport Therapeutics, Inc.
RAPP
8-week follow-up results from Phase 2a trial of RAP-219
Focal onset seizures (FOS)
Q2 2026
Coherus Oncology, Inc.
CHRS
Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripalimab
Second-line head and neck squamous cell carcinoma (HNSCC)
Q2 2026
Oculis Holding AG
OCS
Top-line data readout from Phase 3 trial of OCS-01 (DIAMOND)
Diabetic macular edema (DME)
Q2 2026
Mirum Pharmaceuticals Inc.
MIRM
Topline data from Phase 2b study of Volixibat (VISTAS)
Cholestatic pruritus in patients with primary sclerosing cholangitis
Buy this Content
Editors Pick
Boeing Q1 Net Loss Narrows On Higher Deliveries
April 22, 2026 08:51 ET
GE Aerospace Q1 Adj. Profit Rises; Backs FY26 Outlook
April 21, 2026 09:43 ET
PepsiCo Q1 Net Profit, Revenues Rise
April 16, 2026 07:59 ET
Morgan Stanley Q1 Net Profit Rises 30%
April 15, 2026 08:55 ET